

BTO meeting EuropaBio and Anne Bucher at SANTE (9 September 2019)

Participants

- Anne Bucher, [REDACTED] (B.5)
 - [REDACTED] ([REDACTED] Healthcare Biotech EuropaBio), [REDACTED] ([REDACTED], member EuropaBio)
- Focus EuropaBio on Intellectual Property (IP) related 'ecosystem' and on Life Sciences Strategy as good ingredients for doing business in Europe for biotech companies.
 - Life Sciences Strategy should be developed in coming months with elements like finance, (translational) research, IP, skills labour force.
 - Also focus on access and pricing; EuropaBio in favour of current proposal HTA regulation.
 - From Commission side, stressed that there is an ongoing pharmaceutical debate that goes in various directions (regulatory review, incentives, orphans/paediatrics, pricing).
 - Many aspects could be taken up by new Commission, however, pricing will be out of scope.
 - Upon request, EuropaBio mentioned that they already presented to the Commission outcomes of their 'mirror study' into functioning of the EU Regulations on orphans and paediatrics last May (study will not be published).

[REDACTED], SANTE/B.5 (tel. [REDACTED])